Published in Vaccine Weekly, January 30th, 2008
"Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses," wrote D.T. Ohagan and colleagues, Novartis.
The researchers concluded: "The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately."
Ohagan and colleagues published their study in Clinical Pharmacology &...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly